Koji Fujimoto; Shuhei Hosomi; Yumie Kobayashi; Rieko Nakata; Yu Nishida; Masaki Ominami; Yuji Nadatani; Shusei Fukunaga; Koji Otani; Fumio Tanaka; Satoko Ohfuji; Yasuhiro Fujiwara

doi:10.5217/ir.2024.00076

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Original Article Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database: Koji Fujimoto¹, Shuhei Hosomi^2,, Yumie Kobayashi², Rieko Nakata², Yu Nishida², Masaki Ominami², Yuji Nadatani², Shusei Fukunaga², Koji Otani², Fumio Tanaka², Satoko Ohfuji³, Yasuhiro Fujiwara²; DOI: https://doi.org/10.5217/ir.2024.00076
Published online: August 19, 2024

¹Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Osaka, Japan

²Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

³Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

Correspondence to Shuhei Hosomi, Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. Tel: +81-6-6645-3811, Fax: +81-6-6645-3813, E-mail: shuhosomi@omu.ac.jp

• Received: May 27, 2024 • Revised: July 4, 2024 • Accepted: July 17, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

541 Views
47 Download

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Background/Aims
Treatment using tumor necrosis factor-α (TNF-α) inhibitors is one of the risk factors for active tuberculosis (TB) in patients with Crohn’s disease (CD). Biologics, such as ustekinumab (UST) and vedolizumab (VDZ), are less likely to cause opportunistic infections. However, large-scale studies for active TB and biologics other than TNF-α inhibitors are limited. We aimed to investigate the association between biologics and active TB utilizing a Japanese medical claims database.
Methods
We analyzed retrospectively the association of the risk of active TB development with treatment using TNF-α inhibitors and other biologics (UST and VDZ) in patients with CD using the Japanese Medical Data Vision (MDV) database between April 2008 and June 2022. The durations of each biologic and biologic-free treatment were calculated for each patient. Univariate and multivariate analyses were performed using the Cox proportional hazards model, with the utilization of biologics considered as time-dependent covariates.
Results
We included 28,811 patients with CD in MDV database. Finally, 17,169 patients were analyzed. In total, 7,064 patients were categorized as biologic-naïve, while 10,105 were classified as biologic-experienced. Seventeen patients developed active TB, including 7 on infliximab, 5 on adalimumab, and 5 on no biologics. None of the patients treated with UST and VDZ developed active TB. Multivariate analysis suggested that TNF-α inhibitors were the risk factors for active TB (hazard ratio, 3.66; P=0.020).
Conclusions
TNF-α inhibitors, but not UST or VDZ, are risk factors for active TB in Japanese patients with CD.
Keywords: Crohn disease; Tuberculosis; Biological products; Tumor necrosis factor-alpha; Insurance claim review

INTRODUCTION

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major cause of death worldwide. According to the World Health Organization, TB affects an estimated 10.6 million individuals, resulting in 1.4 million deaths in 2021 [1]. Furthermore, approximately one-quarter of the global population is estimated to have latent tuberculosis infection (LTBI), a condition characterized by no symptoms, despite a continuous immune response to M. tuberculosis [2]. LTBI reactivation occurs when the immune response decreases for various reasons, triggered by factors such as human immunodeficiency virus (HIV) infection or the use of immunosuppressive agents [3].

Crohn’s disease (CD) is characterized by idiopathic inflammation of entire digestive tract, marked by relapses and remissions, often necessitating long-term immunosuppressive therapies [4]. The pathogenesis of underlying CD is unclear; however, various cytokines, such as tumor necrosis factor-α (TNF-α), are associated with chronic intestinal inflammation. Infliximab (IFX) and adalimumab (ADA) are TNF-α inhibitors, which were approved for moderate-to-severe CD in Japan in 2002 and 2010, respectively. They are highly effective in induction and maintenance therapy, leading to a paradigm shift in treatment [5,6]. They play a central role in CD, despite the availability of new biologic agents.

TNF-α plays an important role in tumor and infection immunity. However, patients on TNF-α inhibitors are susceptible to opportunistic infections caused not only by viral and bacterial infections but also by antimicrobial infections. For instance, Keane et al. [7] demonstrated study an association between IFX and TB development in patients with rheumatoid arthritis and CD. Thereafter, numerous epidemiologic studies have reported on the risk of TNF-α inhibitors in the development of antimicrobial infections [8].

Ustekinumab (UST), a monoclonal antibody for interleukin (IL)-12 and IL-23, was approved for inflammatory bowel disease (IBD) in several countries in 2016. Notably, long-term studies have reported on the high safety profile and efficacy of UST [9]. Additionally, vedolizumab (VDZ), an antibody to integrin alpha 4 beta 7, was approved for moderate-to-severe CD in Japan in 2019. Clinical trials have demonstrated the long-term safety of VDZ for IBD [10]. Overall, these drugs are expected to have a lower risk of infection [11,12].

In patients with IBD treated with IFX or ADA, the TB risk is correlated with the local burden of TB [13]. Data from each region is essential for understanding the rate of TB reactivation by each biologic.

However, no large-scale studies have been conducted on the association between biologics other than TNF-α inhibitors and active TB development in patients with CD, particularly in Japan. Therefore, in this study, we aimed to investigate the risk of developing active TB in patients with CD treated with biologics using a Japanese clinical medical claims database.

METHODS

1. Study Design and Data Sources

In this retrospective cohort study, we used the real-world Japanese Medical Data Vision (MDV) database. The MDV database consists of health care claims data from acute care hospitals that use the Diagnosis Procedure Combination (DPC) system. As of March 2022, the database includes approximately 39.4 million inpatients or outpatients from 463 Japanese DPC hospitals, accounting for 26% of the Japanese hospitals that use the DPC system. Approximately 35% of the patients are aged ≥ 65 or over years. The database consists of information on patient characteristics, diagnosis, drug prescriptions, and medical procedures. The diagnoses were recorded according to the International Classification of Diseases, 10th Revision (ICD-10), and Japanese-specific codes. We could not trace the data continuously if patients were transferred to another hospital.

2. Study Population

We obtained the data of patients with a confirmed CD ICD-10 code (K-50) from the MDV database between April 2008 and June 2022. We extracted data on the age, sex, date of diagnosis, and date of prescription. However, since the MDV database includes data before CD diagnosis, we analyzed data after the CD ICD-10 code (K-50) was listed in the data of each patient.

The exclusion criteria were as follows: (1) patients with ICD-10 code (K-51) for ulcerative colitis (confirmed cases) due to diagnosis with indeterminate colitis; (2) patients without prescription data for CD, such as elementary diet, 5-aminosalicylic acid, steroids, thiopurines (azathioprine or 6-mercaptopurine), IFX, ADA, UST, or VDZ; (3) ≤ 12 weeks between the date when the CD ICD-10 code was first listed and the date of the last prescription; and (4) the date of active TB development, as the risk for TB could not be assessed for patients with short-term data. We defined 12 weeks as the threshold, as the longest administration interval for these medications is 12 weeks of UST. Risankizumab and upadacitinib had not been approved for CD in Japan as of June 2022.

3. Defining Active TB Development

We defined active TB development as patients who were newly prescribed 3 or 4 types of anti-TB drugs among isoniazid (INH), rifampicin, pyrazinamide, streptomycin and ethambutol, in addition to the TB ICD-10 codes (A15-19). Patients with an intestinal TB ICD-10 code (A18.3) (confirmed cases) were excluded because they may have been prescribed anti-TB drugs. Moreover, we excluded patients who were prescribed INH for purposes other than active TB treatment. In such cases, INH is prescribed to prevent LTBI reactivation. Therefore, we excluded these patients because we did not intend to investigate of the preventive effects of INH on LTBI reactivation.

4. Follow-up Duration

The duration of biologics use was calculated from the first to the last prescription day for each biologic. When another biologic was prescribed before the last prescription of 1 biologic, the duration of the biologic was calculated as the number of days other than the duration of the second biologic. In biologic-naïve patients, the entire data duration was biologic-free. In biologic-experienced patients, a period beyond 12 weeks before the first prescription or after the last prescription of biologics was defined as a biologic-free duration. Patients who developed active TB were followed up until it. For patients without active TB, data were obtained until the last day of prescription or June 2022.

5. Corticosteroid or Thiopurine Use

We investigated the use of corticosteroids or thiopurines to evaluate TB risk, particularly in relation to concomitant use with biologics. The patients were classified based on the use of systemic corticosteroids or thiopurines whether prescribed even once during both biologic and biologic-free. Notably, budesonide exerts fewer corticosteroid-related adverse effects because it is metabolized in the liver rapidly [14]; thus, it was not included as a systemic corticosteroid use in this study.

6. Comorbidities

We investigate whether diabetes mellitus ICD-10 codes (E10-E14) and HIV infection ICD-10 codes (B20-B24) to examine the influence of comorbid diabetes or HIV infection, which have been reported as risk factors for TB reactivation [15].

7. Statistical Analysis

Clinical characteristics are summarized as medians and interquartile ranges (IQRs) for continuous variables and as counts and percentages for categorical variables. Continuous variables were evaluated using the Wilcoxon rank-sum test, whereras categorical variables were evaluated using the chi-square test. We compared biologic-naïve and biologic-experienced patients based on their age at the first listing of a diagnosis of CD. Moreover, we compared the age of biologic-experienced patients at the first initiation of each biologic. When the number of events was 0, we calculated the 95% confidence interval (CI) based on the rule of 3 (i.e., 0–3/total person-years × 100,000) [16].

We conducted univariate and multivariate analysis using the Cox proportional hazards model, considering TNF-α inhibitors (IFX and ADA), UST, and VDZ as the time-dependent covariates. The duration of the biologic-free period was used as a reference. In the multivariate analyses, we included the sex, age, use of corticosteroids, and use of thiopurine as covariates, as these variables are the known risk factors for active TB development [17-19].

8. Ethical Statements

The data was anonymized, and informed consent was waived according to Ethical Guideline for Medical and Health Research Involving Human Subject in Japan.

RESULTS

1. Patient Demographics and Characteristics

We identified 28,811 patients from the database between April 2008 and June 2022. First, we excluded 11,123 patients based on the exclusion criteria. Second, 519 patients were excluded based on the development of active TB. Finally, we analyzed 17,169 patients (Fig. 1). Table 1 summarizes the characteristics of the eligible patients. The median age of all patients was 37 years, and 69.2% were men. In total, 7,064 patients were categorized as biologic-naïve, and 10,105 patients were categorized as biologic-experienced. The mean age of the biologic-naïve patients was significantly higher than that of the biologic-experienced patients (P<0.001). Moreover, the proportion of men was significantly higher among the biologic-experienced patients (P<0.001). Table 2 summarizes the characteristics of biologic-experienced patients. Approximately, 1,579, 335, and 45 patients had a prescription history of 2, 3, and 4 types of biologics, respectively. No patients with HIV infection ICD-10 codes were listed in the database.

2. Incidence

Seventeen patients developed active TB. The characteristics of patients are shown in Supplementary Table 1. All patients developed TB of respiratory organs. Of the 17 patients, 7 were on IFX. Among these patients, 1 patient each reported the concomitant use of corticosteroids, thiopurine, and both corticosteroids and thiopurines. Five patients were on ADA, of whom 1 patient had a history of concomitant use of corticosteroids, and the other had a history of concomitant use of thiopurines. Of the 5 biologic-free patients, 2 had a history of both IFX and ADA prescription over 10 months before active TB onset, whereas 3 patients were biologic-naïve. Meanwhile, among the 3 biologic-naïve patients, 1 was on thiopurines. Notably, none of the patients treated with UST or VDZ developed active TB. The median duration from the initiation of TNF-α inhibitors to the onset of active TB was 142.5 days (IQR, 107.0–370.8 days), whereas the median biologic-free duration was 304.0 days (IQR, 122.0–874.0 days) for 5 biologic-free patients. Fig. 2 shows the Kaplan-Meier curves of active TB-free survival for patients on TNF-α inhibitors, UST, VDZ, and biologic-free.

Table 3 summarizes the incidence of active TB. The overall incidence of active TB was 21.3 per 100,000 person-years (95% CI, 11.2–31.5). The incidence per 100,000 person-years was 12.9 (95% CI, 1.6–24.3) and 33.1 (95% CI, 14.4–51.9) for biologic-free patients and patients on TNF-α inhibitors, respectively.

3. Cox Proportional Hazards Analysis

We analyzed the risk factors for active TB after excluding the duration of UST or VDZ use as none of the patients treated with UST or VDZ developed active TB. The univariate analysis indicated that there were no significant risk factors for active TB development; however, in the multivariate analysis, TNF-α inhibitors were associated with active TB development (hazard ratio, 3.66; 95% CI, 1.23–10.93; P=0.020) (Table 4). Concomitant corticosteroid, thiopurines, or comorbid diabetes were not associated with active TB development.

DISCUSSION

In this retrospective cohort study using MDV database, TNF-α inhibitors, but not UST or VDZ, were identified as risk factors for active TB development in patients with CD. Although this result is compatible to previous studies [7-12], to our knowledge, this is the first large-scale study using medical claims database on Japanese patients. This novel study demonstrated the association between biologic use and active TB in Japanese patients with CD. With the increasing number of patients treated with biologics, it is imperative for clinicians to recognize the risk of TB associated with biologics even in Japan where the prevalence of TB have been decreasing.

In this study, the overall incidence of active TB was 21.3 (95% CI, 11.2–31.5), compared to 9.2 according to the Japanese annual report of 2021 [20]. Thus, considering that many of the patients in the MDV database used in the present study were patients with CD receiving immunomodulatory therapy, we are confident that the data obtained in this study are reliable.

TNF-α inhibitors play a central role in CD treatment; they bind to soluble and transmembrane TNF-α, preventing TNF-α from binding to its receptors. Simultaneously, these inhibitors bind to transmembrane TNF-α and induce antibody-dependent cellular cytotoxicity-mediated cytotoxicity to prevent the overproduction of TNF-α [21]. However, TNF-α is also an important cytokine associated with mycobacterial infection; TNF-α activates alveolar macrophages and induces granuloma formation [22,23]. Consequently, TNF-α inhibitors impede the immune response to TB and increase its risk.

The incidence of TB infections depends on the TB prevalence in the respective geographical region. Therefore, in regions with low TB transmission, active TB primarily develops owing to LTBI reactivation. To prevent LTBI reactivation, numerous guidelines recommend LTBI screening by combining patient clinical data, chest radiography, and interferon-gamma release assay (IGRA) and/or tuberculin skin test (TST) [24-26]. However, LTBI treatment regimens vary among countries. For instance, in several countries, including Japan, patients diagnosed with LTBI receive INH for 6 to 9 months [24,25,27,28]. Furthermore, Carmona et al. [29] reported that active TB infections in patients on TNF-α inhibitors decreased after LTBI screening before introducing biologics. However, the implementation of LTBI screening and treatment with INH remains incomplete in many healthcare settings [29]. IGRA and TST can provide false-negative or false-positive results, particularly in patients receiving the Bacillus Calmette-Guérin vaccination or on immunosuppressive agents. Additionally, numerous idiopathic inflammatory diseases, such as IBD, require immunosuppressive and immunoregulatory therapy, including corticosteroids, which may also result in false-negative results. Therefore, it is difficult to exclude LTBI by screening with IGRA or TST alone.

UST is a monoclonal antibody against the p40 subunits of IL-12 and IL-23. Although some studies have reported active TB associated with UST in patients with psoriasis [30,31], there are few reports in patients with CD [32]. Both human and mouse models have demonstrated the role of IL-12 in generating a protective interferon-gamma-mediated immune response against TB infections [33,34]. Furthermore, IL-23 is central to anti-TB immunity, despite marginal effects [35]. Nonetheless, no patients treated with UST developed active TB, aligning with findings from a report in China, which identified no instance of patients with active TB development among 721 patients with CD treated with UST [36]. Possible explanations include the relative unimportance of IL-12/23 in anti-TB immunity, the antibody dosage and affinity, and the absence of cytotoxicity via antibody-dependent cellular cytotoxicity compared to TNF-α inhibitors. Nonetheless, further prospective studies with more cases are warranted.

VDZ is a gut-selective monoclonal antibody to integrin α4β7. As its mechanism of action, VDZ inhibits lymphocyte binding to mucosal addressin cell adhesion molecule-1 and migrates to the intestinal mucosa. Notably, VDZ poses a low risk for active TB in patients with IBD [10,11,37,38]. Based on our findings, no patients with CD who were receiving VDZ developed active TB, a result that is consistent with previous reports. Furthermore, a study from South Korea demonstrated that no patients developed active TB among 181 patients with CD treated with VDZ [39].

Compared with TNF-α monotherapy, the concomitant use of corticosteroids, methotrexate, or azathioprine with TNF-α inhibitors increases the risk of serious infection [18,19]. However, in our study, the concomitant use of corticosteroid or thiopurine with TNF-α inhibitors was not associated with active TB. We hypothesized that this lack of association could be attributed to considering the concomitant administration as a moderator variable. However, this approach may have overlooked precise quantification of the duration and dosage of corticosteroids and thiopurines, potentially affecting the accuracy of our findings.

This study has some limitations. Firstly, active TB was diagnosed using ICD-10 codes and prescription data, which may have introduced the minor possibility of an inaccurate diagnosis. Secondly, we could not consider LTBI screening because IGRA and TST results were not included in the MDV database. However, we excluded patients who were receiving INH to prevent LTBI reactivation. Therefore, we investigated the risk of TB caused by biologics without prophylaxis. Thirdly, owing to the characteristics of MDV database, we could not obtain follow-up data upon patient transfer another hospital. Moreover, in some cases, active TB treatment was initiated rapidly after data initiation. Thus, although these patients may have been transferred owing to active TB development, they were not included in the analysis. This is because we excluded patients without prescription data ≥ 12 weeks before the onset of active TB. Finally, potential confounding variables such as disease severity of CD and lifestyle habits like smoking or alcohol drinking were not considered because of the characteristics of database. Additionally, we were not able to investigate dose-dependent effect of TNF-α inhibitors because the database did not include body weight data for some patients. Despite these limitations, our study’s strength lies in the enrolment of a relatively large number of patients, including those treated not only with TNF-α inhibitors but also with UST and VDZ, to evaluate the risk of active TB infection.

In conclusion, TNF-α inhibitors, but not UST or VDZ, are risk factors for active TB in Japanese patients with CD. This result suggests the importance of LTBI screening before the initiation of TNF-α inhibitors and careful follow-up during the administration. Treatment with UST and VDZ may be a better option for immunocompromised hosts, such as older adults or individuals requiring multiple immunosuppressive therapies.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Data Availability Statement

Not applicable.

Author Contributions

Conceptualization: Fujimoto K, Hosomi S, Ohfuji S, Fujiwara Y. Data curation: Fujimoto K. Formal analysis: Fujimoto K, Hosomi S, Ohfuji S. Investigation: Fujimoto K. Methodology: Fujimoto K, Hosomi S, Ohfuji S. Project administration: Hosomi S. Supervision: Fujiwara Y. Writing-original draft: Fujimoto K. Writing-review & editing: Hosomi S, Kobayashi Y, Nakata R, Nishida Y, Ominami M, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Ohfuji S, Fujiwara Y. Approval of final manuscript: all authors.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Characteristics of Patients Who Developed Active Tuberculosis

ir-2024-00076-Supplementary-Table-1.pdf

Fig. 1.

Flowchart of study population. Only confirmed cases diagnosed by ICD-10 codes were included in the analysis. Due to the overlap in patients of each exclusion criterion, the total numbers of excluded patients were not 11,123 and 519, respectively. ICD-10, International Classification of Diseases, 10th Revision; CD, Crohn’s disease; MDV, Medical Data Vision; TB, tuberculosis; INH, isoniazid.

Fig. 2.

Kaplan-Meier curves of active tuberculosis-free survival for patients on tumor necrosis factor-α (TNF-α) inhibitors, ustekinumab (UST), vedolizumab (VDZ), and biologic-free.

Table 1.

Eligible Patients Characteristics

Characteristic	All patients	Biologic-naïve patients	Biologic-experienced patients	P-value
No. of patients	17,169	7,064	10,105
Age when CD was first listed (yr), median (IQR)	37 (25–49)	43 (33–58)	33 (24–43)	< 0.001
Male sex, No. (%)	11,890 (69.2)	4,687 (66.4)	7,203 (71.3)	< 0.001

CD, Crohn’s disease; IQR, interquartile range.

Table 2.

Biologic-Experienced Patients Characteristics

Characteristic	Infliximab	Adalimumab	Ustekinumab	Vedolizumab
No. of patients^a	5,637	4,469	1,965	424
Age when CD was first listed (yr), median (IQR)	33.0 (24.0–43.0)	32.0 (22.0–43.0)	35.0 (25.0–45.0)	38.0 (27.0–46.3)
Age when biologics were initiated (yr), median (IQR)	34.0 (25.0–44.0)	33.0 (23.0–44.0)	38.0 (27.0–49.0)	41.0 (30.0–51.0)
Male sex, No. (%)	4,072 (72.2)	3,061 (68.6)	1,310 (66.7)	282 (66.5)
Corticosteroid, No. (%)	1,362 (24.2)	891 (20.0)	426 (21.7)	112 (26.4)
Thiopurine, No. (%)	2,545 (45.1)	1,512 (33.9)	638 (32.5)	103 (24.3)
Diabetes, No. (%)	726 (12.9)	626 (14.0)	274 (13.9)	88 (20.8)

^a The total number was not 10,105 because some patients were prescribed several types of biologics.

CD, Crohn's disease; IQR, interquartile range.

Table 3.

Incidence of Active Tuberculosis

	No. of patients	Incidence per 100,000 PYs (95% CI)
All patients	17	21.3 (11.2–31.5)
Biologic-free	5	12.9 (1.6–24.3)
TNF-α inhibitors	12	33.1 (14.4–51.9)
Infliximab	7	30.4 (7.9–52.9)
Adalimumab	5	37.9 (4.7–71.2)
Ustekinumab	0	0.0 (0.0–94.2)^a
Vedolizumab	0	0.0 (0.0–784.7)^a

^a In case of zero patients, the 95% CI was calculated based on the rule 3 (i.e., [0–3/total person-years]×100,000).

PY, person-year; CI, confidence interval; TNF, tumor necrosis factor.

Table 4.

Univariate and Multivariate Analysis for Active Tuberculosis Development with the Cox Proportional Hazards Model Considering TNF-α Inhibitor Use as a Time-Dependent Covariate

Variable	Univariate		Multivariate
Variable	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
TNF-α inhibitors^a	2.75 (0.97–7.81)	0.058	3.66 (1.23–10.93)	0.020
Age	1.01 (0.98–1.04)	0.398	1.02 (0.99–1.05)	0.274
Sex, male	0.93 (0.33–2.64)	0.891	0.90 (0.31–2.58)	0.843
Corticosteroid	0.99 (0.32–3.04)	0.989	1.00 (0.32–3.12)	0.999
Thiopurine	0.64 (0.21–1.98)	0.443	0.52 (0.16–1.62)	0.257
Diabetes	1.63 (0.53–5.02)	0.390	1.46 (0.45–4.77)	0.526

^a The duration of the biologic-free period was used as a reference.

TNF, tumor necrosis factor; CI, confidence interval.

REFERENCES

1. Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe 2023;4:e20.Article PubMed
2. Fortún J, Navas E. Latent tuberculosis infection: approach and therapeutic schemes. Rev Esp Quimioter 2022;35(Suppl 3): 94–96.Article PubMed PMC
3. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127–2135.Article PubMed
4. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet 2017;389:1741–1755.Article PubMed
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–1549.Article PubMed
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65.Article PubMed
7. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–1104.Article PubMed
8. Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 2018;155:337–346.Article PubMed
9. Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IMUNITI Trial. Clin Gastroenterol Hepatol 2022;20:578–590.Article PubMed
10. Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1353–1365.Article PubMed PMC PDF
11. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66:839–851.Article PubMed
12. Chu X, Biao Y, Liu C, et al. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis. BMC Gastroenterol 2023;23:346.Article PubMed PMC PDF
13. Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol 2020;115:340–349.Article PubMed
14. Kwapisz L, Jairath V, Khanna R, Feagan B. Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn’s disease. Expert Opin Drug Metab Toxicol 2017;13:793–801.Article PubMed
15. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect 2016;5:e10.Article PubMed PMC PDF
16. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983;249:1743–1745.Article PubMed
17. Lin E, Lin K, Katz S. Serious and opportunistic infections in elderly patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2019;15:593–605.PubMed PMC
18. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020;18:69–81.Article PubMed
19. Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med 2014;46:547–554.Article PubMed
20. Tuberculosis Surveillance Center. Tuberculosis in Japan: Annual Report 2022 [Internet]. c2022;[cited 2023 Oct 20]. https://jata.or.jp/english/dl/pdf/TB_in_Japan_2022FINrev.pdf.
21. Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018;19:2244.Article PubMed PMC
22. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148–155.Article PubMed
23. Ravesloot-Chávez MM, Van Dis E, Stanley SA. The innate immune response to Mycobacterium tuberculosis infection. Annu Rev Immunol 2021;39:611–637.Article PubMed
24. Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021;15:879–913.Article PubMed PDF
25. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(Suppl 3): s1–s106.Article PubMed
26. Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res 2018;16:4–16.Article PubMed PMC PDF
27. Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. J Gastroenterol Hepatol 2018;33:30–36.Article PDF
28. Prevention Committee of the Japanese Society for Tuberculosis; Treatment Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis infection. Kekkaku 2014;89:21–37.PubMed
29. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766–1772.Article PubMed
30. Tsai TF, Chiu HY, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2013;168:444–446.Article PubMed
31. Cho SI, Kang S, Kim YE, Lee JY, Jo SJ. Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea. J Am Acad Dermatol 2020;82:1243–1245.Article PubMed
32. Tominaga K, Tanaka T, Kanazawa M, et al. A case of Crohn’s disease with cardiac tamponade caused by tuberculous pericarditis: assessment of a rare phenomenon. Healthcare (Basel) 2021;9:695.Article PubMed PMC
33. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432–1435.Article PubMed
34. Hölscher C, Atkinson RA, Arendse B, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001;167:6957–6966.Article PubMed PDF
35. Khader SA, Pearl JE, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005;175:788–795.PubMed
36. Liu R, Li Z, Ye L, et al. Risk of tuberculosis and hepatitis B reactivation in patients with Crohn’s disease on ustekinumab: a nationwide real-world study. Inflamm Bowel Dis 2024;30:45–52.Article PubMed PDF
37. Cohen RD, Bhayat F, Blake A, Travis S. The safety profile of vedolizumab in ulcerative colitis and Crohn’s disease: 4 years of global post-marketing data. J Crohns Colitis 2020;14:192–204.Article PubMed PDF
38. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2016;14:1385–1397.Article PubMed
39. Choi MG, Ye BD, Yang SK, Shim TS, Jo KW, Park SH. The risk of tuberculosis in patients with inflammatory bowel disease treated with vedolizumab or ustekinumab in Korea. J Korean Med Sci 2022;37:e107.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database

DOI: https://doi.org/10.5217/ir.2024.00076

XML Download

Figure

Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database

Fig. 1. Flowchart of study population. Only confirmed cases diagnosed by ICD-10 codes were included in the analysis. Due to the overlap in patients of each exclusion criterion, the total numbers of excluded patients were not 11,123 and 519, respectively. ICD-10, International Classification of Diseases, 10th Revision; CD, Crohn’s disease; MDV, Medical Data Vision; TB, tuberculosis; INH, isoniazid.

Fig. 2. Kaplan-Meier curves of active tuberculosis-free survival for patients on tumor necrosis factor-α (TNF-α) inhibitors, ustekinumab (UST), vedolizumab (VDZ), and biologic-free.

Fig. 1.

Fig. 2.

Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database

Characteristic	All patients	Biologic-naïve patients	Biologic-experienced patients	P-value
No. of patients	17,169	7,064	10,105
Age when CD was first listed (yr), median (IQR)	37 (25–49)	43 (33–58)	33 (24–43)	< 0.001
Male sex, No. (%)	11,890 (69.2)	4,687 (66.4)	7,203 (71.3)	< 0.001

Characteristic	Infliximab	Adalimumab	Ustekinumab	Vedolizumab
No. of patients^a	5,637	4,469	1,965	424
Age when CD was first listed (yr), median (IQR)	33.0 (24.0–43.0)	32.0 (22.0–43.0)	35.0 (25.0–45.0)	38.0 (27.0–46.3)
Age when biologics were initiated (yr), median (IQR)	34.0 (25.0–44.0)	33.0 (23.0–44.0)	38.0 (27.0–49.0)	41.0 (30.0–51.0)
Male sex, No. (%)	4,072 (72.2)	3,061 (68.6)	1,310 (66.7)	282 (66.5)
Corticosteroid, No. (%)	1,362 (24.2)	891 (20.0)	426 (21.7)	112 (26.4)
Thiopurine, No. (%)	2,545 (45.1)	1,512 (33.9)	638 (32.5)	103 (24.3)
Diabetes, No. (%)	726 (12.9)	626 (14.0)	274 (13.9)	88 (20.8)

	No. of patients	Incidence per 100,000 PYs (95% CI)
All patients	17	21.3 (11.2–31.5)
Biologic-free	5	12.9 (1.6–24.3)
TNF-α inhibitors	12	33.1 (14.4–51.9)
Infliximab	7	30.4 (7.9–52.9)
Adalimumab	5	37.9 (4.7–71.2)
Ustekinumab	0	0.0 (0.0–94.2)^a
Vedolizumab	0	0.0 (0.0–784.7)^a

Variable	Univariate		Multivariate
Variable	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
TNF-α inhibitors^a	2.75 (0.97–7.81)	0.058	3.66 (1.23–10.93)	0.020
Age	1.01 (0.98–1.04)	0.398	1.02 (0.99–1.05)	0.274
Sex, male	0.93 (0.33–2.64)	0.891	0.90 (0.31–2.58)	0.843
Corticosteroid	0.99 (0.32–3.04)	0.989	1.00 (0.32–3.12)	0.999
Thiopurine	0.64 (0.21–1.98)	0.443	0.52 (0.16–1.62)	0.257
Diabetes	1.63 (0.53–5.02)	0.390	1.46 (0.45–4.77)	0.526

Table 1. Eligible Patients Characteristics

CD, Crohn’s disease; IQR, interquartile range.

Table 2. Biologic-Experienced Patients Characteristics

The total number was not 10,105 because some patients were prescribed several types of biologics.

CD, Crohn's disease; IQR, interquartile range.

Table 3. Incidence of Active Tuberculosis

In case of zero patients, the 95% CI was calculated based on the rule 3 (i.e., [0–3/total person-years]×100,000).

PY, person-year; CI, confidence interval; TNF, tumor necrosis factor.

Table 4. Univariate and Multivariate Analysis for Active Tuberculosis Development with the Cox Proportional Hazards Model Considering TNF-α Inhibitor Use as a Time-Dependent Covariate